Sculier J P, Klastersky J, Stryckmans P
J Clin Oncol. 1985 Feb;3(2):184-91. doi: 10.1200/JCO.1985.3.2.184.
We conducted a late dose intensification pilot study of small-cell lung cancer (SCLC) treated with high doses of cyclophosphamide (200 mg/kg) and etoposide (1.0 to 3.5 g/m2), administered during a period of 48 hours, as well as autologous bone marrow infusion. We have been able to administer safely 3 g/m2 of etoposide with the autologous bone marrow infusion and 1.5 g/m2 without it. Limiting extrahematopoietic toxicity appeared to take the form of irreversible cardiac failure. Complete responses have been obtained with our regimen for late dose intensification, but the duration of the responses and the survival rates of the patients were poor. This suggests that late dose intensification in incomplete responders is not superior to the usually reported results obtained with standard regimens for the treatment of SCLC.
我们开展了一项小细胞肺癌（SCLC）的晚期剂量强化试点研究，使用高剂量环磷酰胺（200mg/kg）和依托泊苷（1.0至3.5g/m²），在48小时内给药，并进行自体骨髓输注。我们已经能够在进行自体骨髓输注的情况下安全给予3g/m²的依托泊苷，在未进行自体骨髓输注的情况下安全给予1.5g/m²的依托泊苷。限制造血外毒性似乎表现为不可逆的心力衰竭。我们的晚期剂量强化方案已获得完全缓解，但缓解持续时间和患者生存率较差。这表明，对未完全缓解者进行晚期剂量强化并不优于治疗SCLC的标准方案通常报告的结果。
